EMS World

MAR 2018

EMS World Magazine is the most authoritative source in the world for clinical and educational material designed to improve the delivery of prehospital emergency medical care.

Issue link: https://emsworld.epubxp.com/i/944334

Contents of this Issue

Navigation

Page 37 of 59

YOU SUSPECT YOUR PATIENT HAS TIME MAY BE RUNNING OUT. 1 CYANIDE POISONING. * ...Patient seems confused...soot around mouth... *Prior to administration of CYANOKIT, smoke inhalation victims should be assessed for exposure to fi re or smoke in an enclosed area; presence of soot around the mouth, nose, or oropharynx; or altered mental status. 1 CYANOKIT is approved for the treatment of known or suspected cyanide poisoning. If clinical suspicion of cyanide poisoning is high, administer CYANOKIT without delay. 1 Suspect it? Treat with CYANOKIT. For more information, visit CYANOKIT.com. IMPORTANT SAFETY INFORMATION Cyanide poisoning may result from inhalation, ingestion, or dermal exposure. Prior to administration of CYANOKIT, smoke-inhalation victims should be assessed for: exposure to fi re or smoke in an enclosed area; presence of soot around the mouth, nose, or oropharynx, and altered mental status. In addition to CYANOKIT, treatment of cyanide poisoning must include immediate attention to airway patency, adequacy of oxygenation and hydration, cardiovascular support, and management of any seizure activity. Use caution in the management of patients with known anaphylactic reactions to hydroxocobalamin or cyanocobalamin. Consideration should be given to use of alternative therapies, if available. Allergic reactions may include: anaphylaxis, chest tightness, edema, urticaria, pruritus, dyspnea, and rash. Allergic reactions including angioneurotic edema have also been reported in postmarketing experience. Acute renal failure with acute tubular necrosis, renal impairment and urine calcium oxalate crystals have been reported following CYANOKIT therapy. Monitor renal function for 7 days following CYANOKIT therapy. Substantial increases in blood pressure may occur following CYANOKIT therapy. Elevations in blood pressure (≥180 mmHg systolic or ≥110 mmHg diastolic) were observed in approximately 18% of healthy subjects receiving hydroxocobalamin 5 g and 28% of subjects receiving 10 g. Usage may interfere with some clinical laboratory evaluations. Also, because of its deep red color, hydroxocobalamin may cause hemodialysis machines to shut down due to an erroneous detection of a "blood leak." This should be considered before hemodialysis is initiated in patients treated with hydroxocobalamin. Due to potential photosensitivity, patients should avoid direct sun until erythema resolves. There are no adequate and well-controlled studies of CYANOKIT in pregnant women. CYANOKIT should be used during pregnancy only if the potential benefi t justifi es the potential risk to the fetus. Safety and effectiveness of CYANOKIT have not been established in pediatric patients. The most common adverse reactions (>5%) included transient chromaturia, erythema, oxalate crystals in urine, rash (predominantly acneiform), increased blood pressure, nausea, headache, decreased lymphocyte percentage, and injection site reactions. Please see Brief Summary of Prescribing Information on adjacent pages. You are encouraged to report negative side effects of prescription drugs to the US Food and Drug Administration (FDA). Visit www.fda.gov/medwatch or call 1-800-FDA-1088. Reference: 1. CYANOKIT (single 5-g vial) [package insert]. Columbia, MD: Meridian Medical Technologies, Inc.; 2017. CYANOKIT is a registered trademark of SERB Sarl, licensed by Meridian Medical Technologies, Inc., a Pfi zer company. © 2017 Meridian Medical Technologies, Inc., a Pfi zer company. All rights reserved. PP-CYA-USA-0052-01 Printed in USA/November 2017 For More Information Circle 27 on Reader Service Card

Articles in this issue

Links on this page

Archives of this issue

view archives of EMS World - MAR 2018